-1 	|BT| (S (NP (NNP Chlorophyllin)) (VP (VP (VBN shown) (ADVP (RB significantly)) (VP (VB reduce) (S (NP (JJ genotoxic) (NN AFB) (NNS biomarkers)) (ADJP (JJ human))))) (, ,) (ADVP (RB therefore)) (VP (VBP hold) (NP (NP (NN promise) (JJ practical) (NN mean)) (VP (VBG reducing) (NP (NN incidence) (JJ AFB-induced) (NN liver) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 158:D23.101 434:E05.318.308.985.525.375|ES| 2:1 18:1 19:1 36:1 124:1 218:1 237:1 836:1 1269:1 1511:1 2215:1 2361:1 2825:1 2827:1 3039:1 3328:1 3329:1 3330:1 3331:1 3332:1
-1 	|BT| (S (NP (NN Claudin-1) (NN overexpression) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ enhances) (NP (NN susceptibility) (JJ adenamatous) (NN polyposis) (JJ coli-mediated) (NN colon) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100|ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1
-1 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
-1 	|BT| (FRAG (ADVP (RB Collectively)) (, ,) (NP (NP (NNS data)) (SBAR (IN along) (S (NP (JJ negative) (NN genotoxicity)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN oxyfluorfen)) (PRN (-LRB- -LRB-) (NP (ADJP (QP (JJR >) (CD 98)) (NN %)) (NN purity)) (-RRB- -RRB-))) (ADJP (JJ potential)) (VP (VBP induce) (S (NP (NN mouse) (NN liver) (NN tumor)) (ADJP (JJ nongenotoxic)))))) (, ,) (NP (NP (JJ mitogenic) (NNP MOA) (JJ clear) (NN threshold)) (VP (VBD predicted) (NP (JJ carcinogenic) (JJ human) (JJ relevant) (NN exposure) (NN level))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1
-1 	|BT| (S (NP (VBN Combined) (NN lapatinib) (NN panobinostat) (NN treatment)) (VP (VBD interacted) (ADVP (RB synergistically)) (VP (VB inhibit) (NP (NP (NN proliferation) (NN colony) (NN formation) (NN CRC) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383|ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (JJ sustained) (NN LPS) (NN accumulation)) (VP (VBZ represents) (NP (JJ pathological) (NN mediator) (NP (NP (JJ inflammation-associated) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN manipulation) (NN gut) (NN flora))))))) (VP (VBP prevent) (SBAR (S (NP (JJ pathogenic) (JJ bacterial) (NN translocation) (NN endotoxin) (NN absorption)) (VP (MD may) (ADVP (RB favorably)) (VP (VB influence) (NP (NP (NN liver) (NN function) (NN patient) (NN cirrhosis) (NN risk)) (VP (VBG developing) (NP (NNP HCC))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469|ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NNP Bromelain)) (VP (VBZ exerts) (NP (NP (JJ antiproliferative) (JJ proapoptotic) (NN effect)) (JJ colorectal) (NN carcinoma) (NN cell) (JJ chemopreventive) (NN action) (NN colon) (NN carcinogenesis)) (FW vivo)))) |ET| |BS|5:C04.588.274.476.411.307 33:C04.697.098 41:A11 46:A03.556.124.526.356 679:D08.811.277.656.262.500.096|ES| 17:1 19:1 75:1 94:1 104:1 113:1 207:1 304:1 378:1 1882:1 1885:1 1946:1 1977:1 2013:1 3120:1 3359:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (JJ Functional) (NN interaction) (NN FOXO3a) (NN ER)) (VP (VBP play) (NP (JJ critical) (NN role)) (S (VP (VBG suppressing) (ADVP (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN growth) (NN tumorigenesis)) (FW vivo))))))) |ET| |BS|15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 41:A11 45:G07.700.320.249 79:I03.450.642.693 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 31:1 78:1 94:1 102:1 104:1 238:1 378:1 618:1 825:1 1882:1 2250:1 3360:1 3361:1 3362:1 3363:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (NNP Metformin)) (, ,) (VP (ADVP (RB generally)) (VBN considered) (S (ADJP (JJ nontoxic) (SBAR (S (ADJP (RB remarkably) (JJ inexpensive)) (, ,) (VP (MD might) (NP (VBN used) (NN combination) (NNS TKIs) (NN patient) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (S (VP (VBG harboring) (S (NP (NN EGFR) (NN mutation)) (VP (VBP overcome) (S (NP (NN TKI) (NN resistance)) (VP (VB prolong) (NP (NN survival)))))))))))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 96:I03.784 110:C04.588.894.797.520.109.220.249 784:D02.078.370.141.450|ES| 2:1 18:1 19:1 34:1 94:1 104:1 120:1 187:1 274:1 328:1 476:1 530:1 694:1 798:1 1061:1 1094:1 1304:1 1882:1 2746:1 2998:1 3364:1 3365:1 3366:1 3367:1 3368:1 3369:1 3370:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN garcinol)) (VP (MD may) (VP (VB merit) (S (NP (JJ clinical) (NN investigation) (NN chemoprophylactic) (NN food) (NN help)) (VP (VB prevent) (NP (JJ colitis-associated) (NN colon) (NN cancer))))))))))) |ET| |BS|53:C06.405.205.265 225:E05.337 680:G07.203.300|ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1
-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (VP (VP (VBN Taken) (ADVP (RB together))) (, ,) (SBAR (S (NP (NNS data) (VBP show) (NN Akt) (NN inhibitor) (NN AZD5363)) (VP (VBZ synergizes) (SBAR (S (NP (JJ lysosomotropic) (NN inhibitor) (NN autophagy) (NN chloroquine)) (VP (VBP induce) (NP (NN apoptosis) (NN delay) (NN tumor) (NN progression) (NN prostate) (NN cancer) (NN model) (JJ resistant) (NN monotherapy) (NN AZD5363)) (, ,) (S (VP (VBG providing) (NP (NP (JJ new) (JJ therapeutic) (NN approach)) (RRC (ADVP (RB potentially)) (NP (JJ translatable) (NN patient)))))))))))))) |ET| |BS|8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180|ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (NN absence) (JJ retinoid-containing) (NN HSC) (NN lipid) (NN droplet)) (VP (VBP promote) (SBAR (S (NP (NN HSC) (NN activation)) (VP (VBZ reduces) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN Raloxifene) (JJ potent) (NN IL-6) (: /) (NN GP130) (NN inhibitor)) (VP (MD may) (VP (VB chemoprevention) (NP (NP (NN agent) (NN liver) (NN cancer)) (VP (VBG targeting) (NP (JJ persistent) (NN STAT3) (NN signaling))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775|ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1
-1 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (NP (NN Pitavastatin) (JJ effective) (VBG inhibiting) (NP (JJ early) (NN phase) (JJ obesity-related) (NN liver) (NN tumorigenesis))) (, ,) (ADVP (RB therefore)) (, ,) (NP (MD may) (NP (JJ useful) (NN chemoprevention) (NN liver) (NN cancer) (JJ obese) (NN individual)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500|ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together))) (, ,) (S (NP (NNS data)) (VP (VBP provide) (NP (NP (JJ first) (ADJP (FW vitro) (FW vivo)) (NN evidence) (JJ integral) (NN role)) (NP (NN LKB1-AMPK) (NN axis) (JJ honokiol-mediated) (NN inhibition) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)))))) |ET| |BS|15:F01.829.316.616 43:F01.145.544 579:A02.835.232.834.151.383 681:G04.299.283|ES| 2:1 18:1 19:1 23:1 31:1 38:1 94:1 103:1 104:1 216:1 239:1 378:1 514:1 620:1 711:1 793:1 816:1 1537:1 1538:1 2089:1 2269:1 3388:1 3389:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (S (NP (NN 5-LOX)) (VP (VBD up-regulated) (NP (NP (JJ adenomatous) (NN colon) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))))))) |ET| |BS|46:A03.556.124.526.356 142:I01.880.604 150:Z01.542.248.960 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 50:1 57:1 104:1 113:1 118:1 131:1 132:1 239:1 579:1 647:1 677:1 807:1 1301:1 3390:1
-1 	|BT| (S (NP (JJ Conditional) (NN beta-catenin) (NN loss) (NN mouse)) (VP (VBZ promotes) (NP (NP (NN chemical) (NN hepatocarcinogenesis)) (: :) (NP (NN role) (NP (ADJP (JJ oxidative) (NN stress) (JJ platelet-derived)) (NN growth) (NN factor) (NN receptor) (NN alpha/phosphoinositide) (NN 3-kinase)) (NN signaling))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 69:G02.111.087.800 578:D08.811.913.696.620.550 716:G03.495.710 965:D08.811.913.696.620.682.725.400.900|ES| 19:1 31:1 32:1 52:1 60:1 102:1 104:1 185:1 186:1 195:1 298:1 900:1 2124:1 2522:1 2583:1 3391:1 3392:1 3393:1 3394:1
-1 	|BT| (NP (NP (NP (JJ Consistent) (NN finding) (, ,) (JJ ABCB5-expressing) (NN tumor) (NN cell) (NN population)) (RRC (ADVP (RB also)) (NP (NN treatment) (ADJP (JJ refractory) (S (VP (VBD exhibited) (NP (NN resistance) (JJ 5-FU-induced) (NN apoptosis) (JJ colorectal) (NN cancer) (NN xenograft) (NN model) (NN 5-FU) (NN monotherapy))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600|ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1
-1 	|BT| (NP (NP (NP (JJ Constitutive) (NN activation) (NN phosphoinositide) (NN 3-kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-))) (: -) (S (NP (NN Akt) (NN pathway)) (VP (VBZ transmits) (NP (NP (JJ growth-regulatory) (NN signal) (NN play) (JJ central) (NN role)) (S (VP (VBG promoting) (NP (NP (NN survival)) (, ,) (NP (NN proliferation)) (, ,) (NP (NN angiogenesis) (JJ human) (NN prostate) (NN cancer) (NN cell))))))))) |ET| |BS|15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1
-1 	|BT| (S (NP (JJ Constitutive) (NN activation) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (JJ primary) (NN cause) (NN colon) (NN cancer)))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1
-1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (JJ partial) (NN loss) (NN A20)) (, ,) (NP (NN A20) (NN heterozygote) (NN mouse)) (, ,)) (ADVP (RB significantly)) (VP (VBZ impairs) (NP (NP (NN liver) (NN regeneration) (NN damage)) (, ,) (NP (VP (VBZ confers) (NP (JJ high) (NN lethality)) (S (VP (ADVP (RB otherwise)) (NP (JJ safe) (NN procedure))))) (NP (FW i.e.) (, ,) (CD 2/3) (JJ partial) (NN hepatectomy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 375:Z01.639.100 925:G10.261.326.520 928:E04.210.556 967:D01.248.497.158.490|ES| 2:1 19:1 32:1 52:1 124:1 178:1 836:1 1508:1 1826:1 1848:1 2729:1 2737:1 3260:1 3272:1 3273:1 3404:1 3405:1 3406:1 3407:1 3408:1 3409:1 3410:1
-1 	|BT| (S (NP (NN Cooperativity) (NN E-cadherin) (NN Smad4) (NN loss)) (VP (VBP promote) (NP (JJ diffuse-type) (JJ gastric) (NN adenocarcinoma) (NN metastasis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115|ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1
-1 	|BT| (NP (NP (NN Correlation) (NN Wnt-2) (NN expression) (NN beta-catenin) (JJ intracellular) (NN accumulation) (JJ Chinese) (JJ gastric) (NN cancer)) (: :) (NP (NN relevance) (NN tumour) (NN dissemination))) |ET| |BS|8:C04 23:D12.776.091.249 924:A11.284.430.214|ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1
-1 	|BT| (NP (NP (JJ Critical) (NN function) (NN ADAM9) (NN mouse) (NN prostate) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500|ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1
-1 	|BT| (NP (NP (NN Cross-talk) (NN aryl) (NN hydrocarbon) (NN receptor) (JJ mitogen-activated) (NN protein) (NN kinase) (NN signaling) (NN pathway) (NN liver) (NN cancer) (NN c-raf) (JJ transcriptional) (NN regulation))) |ET| |BS|69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715|ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1
-1 	|BT| (S (NP (NN Cryptotanshinone)) (VP (VBZ inhibits) (NP (NP (JJ constitutive) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (NN function)) (VP (VBG blocking) (NP (NN dimerization) (NN DU145) (NN prostate) (NN cancer) (NN cell)))))) |ET| |BS|41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250|ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1
-1 	|BT| (S (NP (NNP Cryptotanshinone)) (ADVP (RB rapidly)) (VP (VBD inhibited) (NP (NN STAT3) (NN Tyr705) (NN phosphorylation) (NN DU145) (NN prostate) (NN cancer) (NN cell) (NN growth) (NN cell)) (NP (CD 96) (NN hour) (NN treatment)))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677|ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1
-1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
-1 	|BT| (NP (NP (NP (NN Cyclooxygenase) (CD 2) (NN play) (JJ critical) (NN role) (NN development) (JJ gastrointestinal) (NN cancer)) (NP (JJ human) (NN animal) (NN model)))) |ET| |BS|15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598|ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1
-1 	|BT| (S (NP (NP (NN Cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB constitutively)) (VP (VBD expressed) (NP (NP (NN variety) (NN tumor)) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750|ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1
-1 	|BT| (S (NP (NN Decrease) (JJ hepatic) (JJ stellate) (NN cell) (NN rat)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ clofibrate-induced) (NN hepatocarcinogenesis)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 677:A11.561 910:D02.241.081.114.968.500.500.195|ES| 19:1 94:1 385:1 607:1 838:1 849:1 900:1 2461:1 3433:1 3434:1
-1 	|BT| (FRAG (NP (NN Deficiency) (NN folate)) (, ,) (NP (S (VP (VBP play) (NP (NN role) (NN synthesis) (NNP SAM) (NN lead)))) (NP (VBD increased) (NN risk) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 20:G03.495 61:E05.318.740.600.800 79:I03.450.642.693 86:D01.268.556.435 232:D02.886.030.676.180 974:C18.654.521.500.133.699.308|ES| 2:1 18:1 19:1 31:1 47:1 113:1 171:1 238:1 254:1 778:1 3435:1 3436:1 3437:1
-1 	|BT| (NP (NP (JJ Desmoplakin) (NN act) (NN tumor) (NN suppressor) (NN inhibition) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (JJ human) (NN lung) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500|ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1
-1 	|BT| (S (NP (JJ Diet-induced) (NN obesity) (NN ethanol)) (VP (VBP impair) (NP (NN progression) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ mesenteric) (NN vein) (NN injection) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385|ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1
-1 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
-1 	|BT| (NP (NP (NN Disruption) (NN Ptk6) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1
-1 	|BT| (S (NP (NN DNA) (NN methylation) (NN alteration)) (VP (VBD detected) (SBAR (S (NP (NN zebrafish) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ environmental) (NN carcinogen) (CD 7)) (, ,) (NP (JJ 12-dimethylbenz) (-LRB- -LRB-) (-RRB- -RRB-) (NN anthracene)))))))) |ET| |BS|366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125|ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1
-1 	|BT| (S (NP (NNP Dovitinib)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (NP (NP (NN dephosphorylation) (NN retinoblastoma)) (, ,) (NP (NN upregulation) (NN p-histone) (NN H2A-X) (NN p27)) (, ,)) (NN downregulation) (NN p-cdk-2) (NN cyclin) (NN B1))) (, ,) (VP (VBD resulted) (NP (NN reduction) (JJ cellular) (NN proliferation) (NN induction) (NN tumor) (NN cell) (NN apoptosis))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 85:G02.111.087.225 183:G04.299.233.750 249:G05.355.315.800 339:G02.111.087.880 510:C23.550.444 978:D08.811.913.696.620.682.700.646.500 979:D12.644.360.262.120.100 980:C04.557.465.625.600.725|ES| 2:1 5:1 7:1 19:1 89:1 94:1 299:1 370:1 594:1 595:1 736:1 743:1 1124:1 1126:1 2506:1 3074:1 3449:1 3450:1 3451:1 3452:1 3453:1 3454:1 3455:1
-1 	|BT| (S (NP (NNP Dovitinib)) (VP (VBZ demonstrates) (NP (JJ antitumor) (JJ antimetastatic) (NN activity) (NN xenograft) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255|ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1
-1 	|BT| (S (NP (NP (NN Downregulation) (JJ tumor-suppressor) (NN miR-16)) (PP (IN via) (NP (JJ progestin-mediated) (JJ oncogenic) (NN signaling)))) (VP (VBZ contributes) (NP (NN breast) (NN cancer) (NN development)))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858|ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1
-1 	|BT| (NP (NP (NN Down-regulation) (NN tumor) (NN suppressor) (NN A) (NN kinase) (NN anchor) (NN protein) (CD 12) (JJ human) (NN hepatocarcinogenesis) (JJ epigenetic) (NN mechanism))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 206:G05.360.340.024.340.375.249 671:G05.355.315.203 823:D08.811.913.696.620.682.700.150.125|ES| 4:1 7:1 19:1 36:1 69:1 162:1 470:1 700:1 900:1 1120:1 1603:1 3458:1 3459:1
-1 	|BT| (S (VP (VBN Dysregulated) (SBAR (S (NP (JJ Kruppel-like) (NN factor) (CD 4) (NN vitamin) (NN D) (NN receptor) (NN signaling)) (VP (VBP contribute) (NP (NN progression) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535|ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1
-1 	|BT| (S (NP (NNS Effects)) (VP (VBP magnolol) (NP (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development) (NN mouse)) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 742:G03.787|ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1
-1 	|BT| (NP (NP (NNS Effects) (JJ S-adenosylmethionine) (NN methylthioadenosine) (JJ inflammation-induced) (NN colon) (NN cancer) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 232:D02.886.030.676.180 525:C23.550.470|ES| 18:1 19:1 52:1 113:1 1793:1 3461:1 3462:1 3463:1
-1 	|BT| (S (NP (JJ Elevated) (NN expression) (JJ coactivator-associated) (NN arginine) (NN methyltransferase) (CD 1)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)))) |ET| |BS||ES| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1
-1 	|BT| (NP (NP (NP (VBN Enhanced) (NN liver) (NN tumor) (NN promotion) (NN liver) (NN initiation) (NN activity)) (NP (NN rat) (VBN subjected) (JJ combined) (NN administration) (NN omeprazole) (NN beta-naphthoflavone)))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500|ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN identification) (NN ubiquitin) (JJ carboxyl-terminal) (NN hydrolase) (NN L1) (JJ functional) (NN tumor) (NN suppressor) (NN biomarker) (JJ hepatocellular) (NN carcinoma) (JJ digestive) (NN tumor))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 206:G05.360.340.024.340.375.249 244:C04.588.274.476 374:F01.393.446 985:D08.811.277.352.897.850 986:C04.588.274|ES| 7:1 19:1 303:1 304:1 415:1 700:1 885:1 1201:1 3469:1 3470:1 3471:1 3472:1 3473:1 3474:1
-1 	|BT| (FRAG (NP (NP (NN ErbB2) (NN ErbB3) (NN receptor) (NN tyrosine) (NN kinase)) (NP (VBN associated) (NN development) (JJ human) (NN colon) (NN cancer)) (, ,) (NP (NN expression) (NN receptor) (JJ high) (NN HT-29) (NN cell)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 792:A11.251.210.190.475 987:D08.811.913.696.620.682.725.400|ES| 2:1 18:1 19:1 35:1 36:1 94:1 113:1 115:1 169:1 178:1 186:1 470:1 1705:1 2341:1 2782:1 3475:1
-1 	|BT| (NP (NP (JJ Essential) (NN contribution) (NN chemokine)) (, ,) (NP (NN CCL3)) (, ,) (NP (NN receptor)) (, ,) (NP (NN CCR1)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN progression))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200|ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1
-1 	|BT| (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (JJ novel) (NN farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ human) (NN liver) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN HepG2) (NN Huh7)) (, ,) (NP (NN animal) (NN model) (NN hepatocarcinogenesis)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232|ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1
-1 	|BT| (NP (NP (NP (NN Expression) (NP (JJ ets-related) (JJ transcriptional) (NN factor)) (NN E1AF) (VBN associated) (NN tumor) (NN progression) (NN over-expression) (NN matrilysin)) (NP (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|8:C04 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 166:D12.776.930 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 18:1 19:1 36:1 48:1 86:1 169:1 185:1 316:1 559:1 1013:1 3289:1 3483:1 3484:1
-1 	|BT| (S (NP (NN Expression) (NN glutathione) (NN peroxidase) (CD 2)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)) (ADVP (RB also)) (NP (JJ late) (NN stage) (NN metastasis)))) |ET| |BS|113:C04.697.650 991:D08.811.682.732.500|ES| 5:1 19:1 148:1 169:1 316:1 806:1 900:1 1128:1 1129:1 2649:1 2744:1 3485:1
-1 	|BT| (S (NP (NN Expression) (NN protein) (NN kinase) (NN C)) (VP (NNS isoenzymes) (NP (JJ colorectal) (NN cancer) (NN tissue) (JJ differential) (NN activation) (JJ different) (NN bile) (NN acid)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105|ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1
-1 	|BT| (NP (NP (NP (NNP Farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ potent) (NN liver) (NN cancer) (JJ chemopreventive) (NN agent)))) |ET| |BS|988:D08.811.913.225.431 989:D08.811.913.225.437|ES| 2:1 18:1 19:1 22:1 380:1 728:1 836:1 1946:1 2538:1 3487:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
1 	|BT| (NP (NP (NN AIM) (: :)) (S (S (VP (TO To) (VP (VB elucidate) (S (NP (JJ anticancer) (NN mechanism) (NNP Huqi) (NNP San)) (VP (VBG assessing) (NP (NN expression) (NN G-6-Pase))))))) (, ,) (NP (NP (NN SDH)) (, ,) (NP (NN ATPase) (NN AFP) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 2:1 19:1 104:1 115:1 162:1 828:1 849:1 900:1 959:1 1196:1 1697:1 1880:1 2762:1 2765:1 2766:1 3630:1 3632:1 3634:1 3957:1
1 	|BT| (S (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ therapeutic) (NN effect) (JJ potential) (NN mechanism) (JJ natural) (NN flavonoid) (NN quercetin-3-O-beta-D-glucuronide)) (PRN (-LRB- -LRB-) (NP (NN Q3GA)) (-RRB- -RRB-))) (VP (NN lipid) (NP (NP (NN metabolism) (NN disorder) (JJ free) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FFA)) (-RRB- -RRB-)))))))) (: -) (VP (VBN induced) (NP (NN fatty) (NN liver)) (ADVP (FW vivo) (FW vitro)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 1132:C18.452.584 1133:D10.251.310|ES| 10:1 14:1 19:1 75:1 104:1 162:1 216:1 378:1 409:1 459:1 541:1 827:1 828:1 836:1 959:1 1275:1 1886:1 2007:1 2070:1 2333:1 2401:1 3163:1 3958:1 3959:1 3960:1 3961:1
1 	|BT| (NP (NP (NN Alcohol) (JJ well-established) (NN risk) (NN factor) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN mechanism) (NN alcohol) (NN liver) (NN cancer) (NN complex))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 751:D02.033.375 822:D02.033|ES| 2:1 18:1 19:1 162:1 171:1 185:1 303:1 304:1 695:1 836:1 1770:1 3710:1 3962:1
1 	|BT| (NP (NP (NP (JJ Altered) (NN gene) (NN expression) (NN DNA) (NN repair)) (: -) (NP (NP (NN cell) (JJ proliferation-associated) (NNS proteins/enzymes)) (VP (VBN examined) (NP (NN process) (JJ tamoxifen-induced) (NN hepatocarcinogenesis) (JJ female) (JJ Sprague-Dawley) (NN rat)))))) |ET| |BS|155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543|ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (JJ Chronic) (NN alcohol) (NN drinking)) (VP (VBZ accelerates) (NP (NP (NN liver) (NN fibrosis) (NN patient)) (JJ viral) (NN hepatitis)) (VP (ADVP (RB fully)) (VBD explained) (NP (JJ ethanol-enhanced) (NN liver) (NN damage)))))) |ET| |BS|50:M01.643 242:A03.620 676:C06.552.630 751:D02.033.375 904:F01.145.317.269 1136:B04.450|ES| 19:1 104:1 120:1 529:1 836:1 889:1 949:1 1046:1 1777:1 1778:1 1848:1 2048:1 3710:1 3967:1 3968:1 3969:1 3970:1 3971:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NN Alcohol) (NN consumption)) (VP (VBZ promotes) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 904:F01.145.317.269|ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1
1 	|BT| (S (NP (NP (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Chemopreventive) (NN effect) (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN inhibitor) (NN JTE-522) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis)) (VP (VBD evaluated) (NP (NNP Wistar) (NN rat)))) |ET| |BS|225:E05.337 349:D27.505.519.389.310.500 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900|ES| 10:1 14:1 19:1 61:1 75:1 76:1 104:1 380:1 409:1 780:1 849:1 900:1 1046:1 1749:1 1875:1 1952:1 2603:1 3972:1 3973:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (JJ Chronic) (NP (NP (NN ethanol) (NN consumption) (NN increase) (NN risk) (JJ hepatic) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269|ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (ADVP (RB rapidly)) (VP (VBG increasing) (NP (NP (NN cancer)) (WHNP (WHNP (WP$ whose) (JJ known) (NN risk) (NN factor)) (NP (JJ chronic) (NN ethanol) (NN abuse))) (, ,) (NP (JJ viral) (NN hepatitis) (NN infection)) (, ,) (NP (NN aflatoxin) (NN exposure)))))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02|ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (: :) (NP (NP (JJ Prolonged) (JJ high) (NN intake) (JJ dietary) (NN selenium)) (VP (VBN shown) (VP (VBP induce) (NP (JJ gestational) (NN diabetes) (NN rat) (NN hyperinsulinemia) (NN pig))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 935:D01.268.185.850 1053:C18.452.394.968 1142:B01.050.150.900.649.077.880.399 1143:B01.050.150.900.649.077.880 1144:C13.703.170|ES| 19:1 104:1 178:1 237:1 243:1 849:1 1046:1 2009:1 2563:1 2594:1 3284:1 3670:1 3975:1 3976:1 3977:1
1 	|BT| (S (NP (NP (NP (JJ Carcinogenic) (NN risk) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (NN copper) (NN gluconate)))) (, ,) (NP (JJ additive) (JJ functional) (NN food)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (NP (NN rat) (JJ medium-term) (NN liver) (NN carcinogenicity) (NN bioassay) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NN Ito) (NN test)) (-RRB- -RRB-))) (ADJP (ADJP (JJ 2-week)) (ADJP (JJ short-term))) (NN administration) (NN experiment)))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 849:G08.686.785.760.769.490.500 914:L01.178 1145:D02.241.081.844.322 1146:D27.720.368 1147:C17.800.621|ES| 2:1 10:1 14:1 19:1 161:1 162:1 171:1 350:1 399:1 403:1 415:1 435:1 836:1 849:1 1418:1 2470:1 2575:1 2632:1 2931:1 3022:1 3215:1 3216:1 3266:1 3583:1 3776:1 3801:1 3978:1 3979:1 3980:1 3981:1
1 	|BT| (NP (NP (JJ Chronic) (JJ excessive) (NN alcohol) (NN consumption) (NN lead) (NN development)) (NP (NP (JJ alcoholic) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ALD)) (-RRB- -RRB-))) (S (VP (ADVP (RB greatly)) (VB increase) (NP (NN risk) (NN liver) (NN cancer))))) |ET| |BS|61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066|ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1
1 	|BT| (S (NP (JJ Chronic) (NN exposure) (NN toxaphene)) (VP (VBD resulted) (NP (NN increase) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 40:1 52:1 594:1 836:1 1953:1 3967:1 3985:1 3986:1
1 	|BT| (SINV (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (CD one) (JJ common) (NN cancer)) (ADVP (RB worldwide)) (, ,) (VP (VBD caused)) (NP (NP (NP (NNP Hepatitis) (NNP C) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (NN hepatotoxin))) |ET| |BS|104:C04.557.470.200.025.255 550:B04.450.410|ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1
1 	|BT| (NP (NP (NP (NN Mouse) (JJ nongenotoxic) (NNS hepatocarcinogens)) (SBAR (S (NP (JJ phenobarbital) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)) (NN chlordane)) (VP (VBP induce) (ADVP (RB hepatomegaly)) (VP (VBN characterized) (NP (NN hypertrophy) (NN hyperplasia)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 510:C23.550.444 756:D03.383.742.698.253.650 1150:D02.455.526.439.180 1151:C06.552.416 1152:C23.300.775|ES| 10:1 14:1 19:1 243:1 985:1 1795:1 2127:1 2685:1 3340:1 3496:1 3989:1 3990:1 3991:1 3992:1
1 	|BT| (NP (NP (NP (NNS OBJECTIVES)) (: :) (NP (NP (NP (NP (DT The) (JJ chemopreventive) (JJ potential) (NN Tephrosia) (NN purpurea) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN TPE)) (-RRB- -RRB-))) (NN N-nitrosodiethylamine) (-LRB- -LRB-) (NN NDEA) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ Wistar) (NN rat)) (VP (VBN assessed))))))))) |ET| |BS|104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 10:1 14:1 19:1 104:1 303:1 304:1 409:1 441:1 691:1 827:1 849:1 1946:1 2496:1 2602:1 2603:1 3823:1 3993:1 3994:1 3995:1 3996:1 3997:1
1 	|BT| (S (NP (PRP$ Our) (JJ prior) (NN work)) (VP (VBD showed) (NP (NP (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (JJ inorganic) (JJ arsenic-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN formation) (JJ adult) (JJ male) (NN offspring))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 445:I03.946 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1156:F01.829.263.065 1157:E05.916.039 1158:D01.268.513.249|ES| 10:1 14:1 19:1 43:1 52:1 132:1 303:1 304:1 355:1 441:1 658:1 1402:1 1546:1 1953:1 3174:1 3998:1 3999:1 4000:1 4001:1 4002:1 4003:1
1 	|BT| (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (NN orphenadrine) (-LRB- -LRB-) (NN ORPH) (-RRB- -RRB-) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN 2B) (NN inducer) (NN liver) (JJ tumor-promoting) (NN effect) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1159:D02.092.471.600 1160:D27.505.389.249|ES| 10:1 14:1 19:1 75:1 836:1 849:1 2549:1 3496:1 3776:1 3788:1 3789:1 3791:1 4004:1 4005:1 4006:1 4007:1
1 	|BT| (S (NP (NN Rat) (NN liver) (NN tumor)) (VP (VBD initiated) (NP (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (S (NP (NP (NN promotion) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (VBN examined) (NN expression) (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF) (NN beta)) (-RRB- -RRB-))) (NP (NN type) (CD I) (, ,) (NP (QP (CD II) (CD III))) (NP (NN receptor))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 554:D02.654.442.200 756:D03.383.742.698.253.650 1161:D12.644.276.374.687.100|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 186:1 324:1 543:1 836:1 1116:1 1772:1 1773:1 1875:1 1900:1 1972:1 2281:1 2337:1 2350:1 2602:1 2685:1 3130:1 3496:1 4008:1 4009:1
1 	|BT| (S (NP (NP (DT The) (JJ key) (NN event) (JJ responsible) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (NN pesticide)) (PRN (-LRB- -LRB-) (NP (NP (NN viz.)) (, ,) (NP (NN pronamide))) (-RRB- -RRB-))))) (VP (VBD investigated) (NP (S (NP (NN series) (NN study)) (VP (VBG employing) (ADJP (ADJP (JJ molecular)) (, ,) (ADJP (JJ biochemical)) (, ,) (ADJP (JJ cellular))))) (, ,) (NP (JJ apical) (NN endpoint))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1
1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBD determine) (SBAR (S (NP (NP (NP (NP (JJ chemopreventive) (NN activity) (JJ Korean) (JJ red) (NN ginseng) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN KRG)) (-RRB- -RRB-))) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500|ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1
1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VB determine) (SBAR (IN whether) (S (NP (NN alteration) (NN expression) (NN RXRalpha) (NN retinoid) (NN receptor) (NN RARalpha) (NN RARbeta)) (VP (VBN involved) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG using) (NP (NP (NP (CD 3) ('' ') (: -) (NN methyl-4-dimethylaminoazobenzene) (-LRB- -LRB-) (CD 3) ('' ') (: -)) (NP (NN MeDAB) (-RRB- -RRB-) (: -))) (VP (VBN induced) (NP (NN rat) (NN liver) (NN carcinogenesis) (NN model)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1163:D02.092.146.325.500 1164:D12.776.826.701|ES| 10:1 14:1 19:1 72:1 74:1 115:1 131:1 186:1 207:1 221:1 350:1 409:1 691:1 774:1 836:1 849:1 900:1 951:1 1307:1 1683:1 2573:1 4017:1 4018:1 4019:1 4020:1 4021:1
1 	|BT| (S (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN undertaken))) (VBP investigate) (NP (NP (NN effect) (JJ dietary) (NN supplementation) (NN nimesulide) (NN eugenol) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN initiated) (NP (JJ early) (NN hepatocarcinogenesis) (NN F344) (JJ male) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500|ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1
1 	|BT| (S (NP (NP (DT The) (JJ preventive) (NN effect)) (VP (VP (VBN processed) (NP (NP (NP (NP (NNP Aloe) (NN vera) (NN gel)) (PRN (-LRB- -LRB-) (NP (NN PAG)) (-RRB- -RRB-))) (NN colon) (NN carcinogenesis)) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-)))))))) (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))))) (: -) (VP (VBD promoted) (NP (NN mouse) (NN colon) (NN carcinogenesis) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 10:1 14:1 19:1 52:1 72:1 75:1 113:1 207:1 324:1 350:1 406:1 407:1 674:1 691:1 1883:1 1993:1 1994:1 3300:1 3306:1 4024:1 4025:1 4026:1 4027:1 4028:1 4029:1
1 	|BT| (S (NP (NP (NP (DT The) (NN process) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (JJ initiation/phenobarbital) (-LRB- -LRB-) (NN PB) (-RRB- -RRB-) (NN promotion) (NN mouse) (NN model)) (VP (VBZ involves) (NP (NP (JJ selective) (JJ clonal) (NN outgrowth) (NN cell) (NN harboring) (NN oncogene) (NN mutation) (NN Ctnnb1)) (, ,) (S (NP (JJ spontaneous) (JJ DEN-only-induced) (NN tumor)) (ADVP (RB often)) (NP (NP (NN Ha-ras)) (: -) (NP (JJ B-raf-mutated))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 9:G05.360.340.024.340.375.500 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 41:A11 216:Z01.107.084.900.425 278:D08.811.913.696.620.682.700.559.842.374 301:A11.251.353 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 2:1 7:1 10:1 14:1 19:1 24:1 34:1 52:1 72:1 94:1 283:1 632:1 638:1 691:1 900:1 1069:1 1304:1 1673:1 1749:1 1875:1 1952:1 2337:1 3496:1 4030:1 4031:1 4032:1 4033:1 4034:1 4035:1
1 	|BT| (S (NP (NP (NP (DT The) (JJ tumour-promoting) (NN effect) (NN beta-naphthoflavone)) (PRN (-LRB- -LRB-) (NP (NN BNF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ novel) (NN aryl) (NN hydrocarbon) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN AhR)) (-RRB- -RRB-))) (NN agonist)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (JJ medium-term) (NN hepatocarcinogenesis) (NN model) (NN rat)))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 849:G08.686.785.760.769.490.500 914:L01.178 969:D12.776.260.643.715 983:D03.383.663.283.266.450.175.100|ES| 2:1 10:1 14:1 19:1 72:1 75:1 186:1 350:1 403:1 691:1 849:1 891:1 900:1 3215:1 3228:1 3417:1 3418:1 3468:1 4036:1 4037:1 4038:1
1 	|BT| (S (NP (EX There)) (NP (JJ abundant) (JJ epidemiological) (NN evidence) (JJ heavy) (NN alcohol) (NN intake)) (VP (VBZ contributes) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development)))) |ET| |BS|104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269|ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ validates) (NP (NP (NP (NN utility) (NN Gum) (JJ Arabic-conjugated) (NN gold) (NNS nanoparticles)) (PRN (-LRB- -LRB-) (NP (NNS GA-AuNPs)) (-RRB- -RRB-))) (SBAR (S (NP (NN laser)) (VP (VBP induce) (NP (JJ photothermal) (NN inhibition) (NN hepatocarcinogenesis)))))) (, ,) (PP (IN via) (S (VP (VBG employing) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (FRAG (: -) (NP (VBN mediated) (JJ hepatocellular) (NN carcinoma) (NN model))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 104:C04.557.470.200.025.255 554:D02.654.442.200 1166:Z01.058.290.190.300 1167:D05.750.078.739.500 1168:J01.637.512.600 1169:D01.268.556.322 1170:E07.632.490|ES| 2:1 10:1 14:1 19:1 72:1 103:1 131:1 243:1 303:1 304:1 596:1 807:1 900:1 1875:1 1952:1 2194:1 4011:1 4040:1 4041:1 4042:1 4043:1 4044:1 4045:1 4046:1 4047:1 4048:1
1 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
1 	|BT| (S (VP (TO To) (VP (VB clarify) (NP (NP (JJ possible) (NN mechanism) (JJ non-genotoxic) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ male) (NN F344) (NN rat)) (VP (VBN administered) (S (NP (NN i.p))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 590:B01.050.050.199.520.760.200 967:D01.248.497.158.490 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 162:1 412:1 828:1 849:1 900:1 1359:1 1402:1 2336:1 3185:1 3193:1 3777:1 3778:1 4049:1 4050:1 4051:1
1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ protective) (NN effect) (NN bilberry) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN BBE)) (-RRB- -RRB-))) (NP (NP (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin)) (PRN (-LRB- -LRB-) (NP (NN EMIQ)) (-RRB- -RRB-))) (NP (NP (JJ hepatocarcinogenic) (NN process)) (VP (VBG involving) (NP (NP (JJ oxidative) (NN stress) (NN response)) (, ,) (VP (VBN used) (S (NP (NP (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (JJ N-diethylnitrosamine-initiated) (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))))))))))))) (: -) (VP (VBD promoted) (NP (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 72:1 75:1 459:1 476:1 493:1 494:1 638:1 828:1 849:1 900:1 2335:1 2372:1 2496:1 2522:1 2583:1 2971:1 3773:1 3774:1 3777:1 3778:1 4029:1 4050:1 4052:1 4053:1 4054:1 4055:1 4056:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (NN effect) (NN liver) (NN damage)) (VP (VBD induced) (NP (NN flutamide) (JJ primary) (NN rat) (NNS hepatocytes)) (S (VP (VBG using) (NP (NP (NN liver)) (NP (JJ microfluidic) (NN biochip)))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1171:E05.830.666 1172:D02.065.199.420|ES| 19:1 75:1 344:1 350:1 403:1 412:1 836:1 843:1 849:1 894:1 1848:1 4057:1 4058:1 4059:1
1 	|BT| (NP (NP (JJ 2-Amino-1-methyl-6-phenylimidazo) (PRN (-LRB- -LSB-) (ADJP (JJ 4,5-b)) (-RRB- -RSB-)) (NN pyridine) (NN increase) (NN number) (NN tumor)) (, ,) (NP (JJ cystic) (NN crypt) (JJ aberrant) (NN crypt) (NN focus) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 555:C04.182 744:D03.383.725 824:C04.834.020|ES| 2:1 7:1 19:1 40:1 52:1 109:1 640:1 646:1 649:1 1373:1 1378:1 1431:1 1725:1 2639:1 2640:1 2913:1 4060:1 4061:1
1 	|BT| (S (NP (NP (JJ 2-Nitrobenzo) (-LRB- -LSB-) (-RRB- -RSB-) (NN pyrene) (NN 6-nitrochrysene)) (VP (VBD induced) (NP (NP (JJ high) (NN incidence) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (CD 91-100) (NN %)) (-RRB- -RRB-))) (, ,) (PP (VBG remaining) (NP (NN test) (NN compound))))) (VP (VBP induce) (NP (NN tumor) (NN rate)) (NP (RB significantly) (JJR higher) (JJ solvent) (NN control)))) |ET| |BS|8:C04 434:E05.318.308.985.525.375 515:C04.588.274.623 1173:D02.455.426.559.847.799 1174:D27.720.844|ES| 2:1 7:1 10:1 14:1 19:1 41:1 124:1 170:1 178:1 243:1 289:1 369:1 412:1 836:1 1373:1 1378:1 1418:1 1511:1 2433:1 4062:1 4063:1 4064:1 4065:1 4066:1 4067:1
1 	|BT| (S (NP (DT A) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer) (NN model)) (VP (VBD used) (VP (VB evaluate) (NP (NN role) (NN Myc) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 554:D02.654.442.200|ES| 18:1 19:1 31:1 69:1 72:1 476:1 836:1 890:1 900:1 1786:1 2732:1
1 	|BT| (S (ADVP (RB Additionally)) (, ,) (VP (VBD reported) (SBAR (S (NP (NN tamoxifen)) (VP (MD may) (VP (VB cause) (NP (NP (NP (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-))) (NP (JJ human) (JJ experimental) (NN animal))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 1175:B01.050.050.199|ES| 2:1 10:1 14:1 19:1 36:1 46:1 263:1 491:1 836:1 993:1 998:1 1779:1 2069:1 2070:1 2371:1 2609:1 4068:1
1 	|BT| (S (NP (NP (NP (NNP Administration) (NN acetaminophen) (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN mouse)) (VP (VBD produced) (NP (NP (JJR greater) (NN level) (NN liver) (NN injury)) (VBN observed) (NP (NP (NN Jnk1)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse)) (, ,) (NP (VBN based) (NN level) (NN serum) (NN marker) (JJ microscopic) (JJ histologic) (NN analysis) (NN liver) (NN tissue)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 333:D01.045 426:E01.370.350.515 661:D02.065.199.092.040 1176:D23.101|ES| 2:1 10:1 14:1 19:1 52:1 134:1 249:1 261:1 272:1 289:1 534:1 661:1 836:1 1992:1 2204:1 2346:1 2412:1 2414:1 2415:1 2416:1 2741:1 4069:1 4070:1 4071:1
1 	|BT| (FRAG (PP (IN After) (NP (NP (JJ 3-month) (NN recovery) (NN period) (JJ tamoxifen-treated) (NN rat) (JJ large) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN diameter) (CD 3) (NN cm)) (-RRB- -RRB-))))) |ET| |BS|8:C04 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 776:G01.910.645 1151:C06.552.416|ES| 7:1 10:1 14:1 19:1 836:1 849:1 862:1 1408:1 1409:1 2722:1 2724:1 2725:1 3265:1 4072:1 4073:1
1 	|BT| (S (NP (NN AIRmax)) (ADVP (RB also)) (NP (JJ susceptible) (NN AIRmin) (NN colon) (NN cancer)) (VP (VP (VBD induced) (NP (NP (QP (CD 2) (CD 7)) (JJ weekly) (NNS dos)) (ADJP (ADJP (JJ 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG showing) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN number) (JJ colonic) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (CD 150) (NN day) (NN DMH) (NN treatment))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (ADJP (RB significantly) (JJR higher)) (NN number) (NN tumor) (VBG affecting) (NP (NP (JJR larger) (JJ intestinal) (NN area)) (CD 300-475) (NN day)))) |ET| |BS|8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526|ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1
1 	|BT| (NP (NP (NN Amelioration) (JJ free) (NN fatty) (JJ acid-induced) (NN fatty) (NN liver) (NN quercetin-3-O-beta-D-glucuronide) (NN modulation) (NN peroxisome) (JJ proliferator-activated) (JJ receptor-alpha/sterol) (JJ regulatory) (JJ element-binding) (JJ protein-1c) (NN signaling))) |ET| |BS|69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310|ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1
1 	|BT| (NP (JJ Arsenic) (VP (VBN induced) (NP (NP (NP (JJ dose-related) (NN increase) (NN lung) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (NN gallbladder) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN male)) (-RRB- -RRB-))) (, ,) (NP (JJ uterine) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 265:C04.557.470.200 1158:D01.268.513.249 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1182:C04.588.274.120.401 1183:A05.360.319.679|ES| 2:1 7:1 10:1 14:1 19:1 40:1 255:1 303:1 304:1 328:1 412:1 1402:1 4086:1 4087:1 4088:1 4089:1 4090:1
1 	|BT| (S (NP (NN beta-Naphthoflavone)) (VP (VBZ enhances) (NP (NP (JJ oxidative) (NN stress) (NN response)) (NN induction) (JJ preneoplastic) (NN lesion) (JJ diethylnitrosamine-initiated) (NN hepatocarcinogenesis) (NN model)) (ADVP (RB partially)) (VP (VBD hepatectomized) (NP (NN rat))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 983:D03.383.663.283.266.450.175.100|ES| 19:1 72:1 494:1 736:1 849:1 900:1 1131:1 1351:1 1356:1 1438:1 2522:1 2583:1 4091:1 4092:1 4093:1
1 	|BT| (NP (NP (NN Cell) (NN expression) (NN pattern) (NN CD147) (JJ N-diethylnitrosamine/phenobarbital-induced) (NN mouse) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 104:C04.557.470.200.025.255 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 19:1 52:1 115:1 260:1 303:1 304:1 4094:1 4095:1 4096:1
1 	|BT| (S (S (NP (NN Cell) (NN proliferation) (NN hepatocarcinogenesis) (NN rat)) (VP (VBD initiated) (SBAR (S (NP (NN diethylnitrosamine)) (VP (VBD promoted) (NP (NN phenobarbital))))))) (: :) (NP (NP (JJ potential) (NN role) (JJ early) (NN DNA) (NN damage) (NN liver) (NN metallothionein) (NN expression)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 554:D02.654.442.200 756:D03.383.742.698.253.650 777:D12.776.556.670|ES| 19:1 31:1 104:1 115:1 299:1 666:1 827:1 836:1 849:1 900:1 1128:1 1848:1 1900:1 1912:1 1952:1 2685:1 2731:1 4094:1
1 	|BT| (NP (NP (NNP Chemoprevention) (NNP Diethylnitrosamine-Initiated) (NNP Phenobarbital-Promoted) (NNP Hepatocarcinogenesis) (NNP Rats) (NNP Sulfated) (NNP Polysaccharides) (NNP Aqueous) (NN Extract) (NNP Ulva) (NN lactuca))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 554:D02.654.442.200 756:D03.383.742.698.253.650 803:D01.248.497.158.845 804:D09.698 1184:B01.650.940.150.900|ES| 19:1 1959:1 2842:1 3664:1 4097:1 4098:1 4099:1 4100:1 4101:1 4102:1 4103:1 4104:1
